Shares of MOIL closed marginally lower at ₹386.55 on the NSE. The company’s stock has grown as much as 12% in the previous six months.

While failing to cross Monday’s high may not have pleased the bulls, the fact that the index has managed to hold on to 25,500 on…

The new indication allows durvalumab, in combination with carboplatin and paclitaxel, to be used as a first-line treatment for adults with primary, advanced, or recurrent…

The development follows a CNBC-TV18 newsbreak on June 6, citing sources  that Grasim Industries had complained against Asian Paints’ alleged restrictive practices to the competition regulator.…

Value Research advises limiting gold exposure to 5–10% of an overall portfolio, mainly as a risk-management tool rather than a growth asset.

Paras Anti-Drone Technologies, a subsidiary of Paras Defence and Space Technologies, has received a ₹22.21 crore Letter of Intent from France’s Cerbair to supply 30…

The new entity will house Lupin’s consumer healthcare portfolio, which includes OTC brands such as Softovac, Beplex Forte, Corcium, and Aptivate. The company said the…

The timing is bold. India’s private equity space is no longer under the radar, it’s crowded, competitive, and teeming with both global giants and ambitious…

The approved product is a generic version of Lotemax SM ophthalmic gel, 0.38%, originally developed by Bausch & Lomb Inc. Shares of Lupin Ltd ended…

With 29.3 GWh of committed storage capacity, the company is steadily advancing toward its 40 GWh renewable energy goal by 2030. Shares of JSW Energy…